Relypsa Inc. (NASDAQ:RLYP) has been given a consensus rating of “Hold” by the seventeen research firms that are presently covering the firm. Twelve analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $36.76.
A number of analysts recently issued reports on the company. HC Wainwright lowered Relypsa from a “buy” rating to a “neutral” rating and set a $32.00 price target for the company. in a report on Friday, July 22nd. Brean Capital lowered Relypsa from a “buy” rating to a “hold” rating in a report on Thursday, July 21st. Wedbush lowered Relypsa from an “outperform” rating to a “neutral” rating and set a $32.00 price target for the company. in a report on Thursday, September 1st. Stifel Nicolaus reiterated a “buy” rating on shares of Relypsa in a report on Tuesday, June 28th. Finally, BTIG Research lowered Relypsa from a “buy” rating to a “neutral” rating in a report on Thursday, September 1st.
Shares of Relypsa (NASDAQ:RLYP) opened at 31.99 on Tuesday. Relypsa has a 12-month low of $10.26 and a 12-month high of $32.12. The firm has a 50 day moving average price of $30.31 and a 200-day moving average price of $20.28.
Relypsa (NASDAQ:RLYP) last announced its quarterly earnings results on Thursday, August 4th. The company reported ($1.87) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.56) by $0.31. The company earned $5.22 million during the quarter, compared to analysts’ expectations of $5.45 million. On average, analysts anticipate that Relypsa will post ($6.33) earnings per share for the current year.
In other Relypsa news, major shareholder James D. Dondero sold 37,000 shares of Relypsa stock in a transaction on Thursday, August 11th. The shares were sold at an average price of $31.96, for a total value of $1,182,520.00. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, major shareholder Orbimed Advisors Llc sold 4,043,600 shares of Relypsa stock in a transaction on Monday, July 25th. The shares were sold at an average price of $32.00, for a total transaction of $129,395,200.00. The disclosure for this sale can be found here.
A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Janus Capital Management LLC raised its position in Relypsa by 3.0% in the second quarter. Janus Capital Management LLC now owns 4,513,955 shares of the company’s stock worth $83,507,000 after buying an additional 130,742 shares in the last quarter. Vanguard Group Inc. raised its position in Relypsa by 17.4% in the second quarter. Vanguard Group Inc. now owns 2,445,249 shares of the company’s stock worth $45,237,000 after buying an additional 361,815 shares in the last quarter. State Street Corp raised its position in Relypsa by 106.1% in the first quarter. State Street Corp now owns 2,216,498 shares of the company’s stock worth $30,037,000 after buying an additional 1,141,229 shares in the last quarter. Deerfield Management Co. raised its position in Relypsa by 108.1% in the first quarter. Deerfield Management Co. now owns 1,873,471 shares of the company’s stock worth $25,386,000 after buying an additional 973,190 shares in the last quarter. Finally, BlackRock Fund Advisors raised its position in Relypsa by 2.8% in the second quarter. BlackRock Fund Advisors now owns 1,823,279 shares of the company’s stock worth $33,731,000 after buying an additional 49,978 shares in the last quarter.
Relypsa, Inc is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of polymer-based drugs to treat conditions that are often overlooked and undertreated, but that can have a serious impact on patients’ lives and even be life-threatening. The Company’s first drug candidate is Veltassa (patiromer) for oral suspension, or Veltassa, for the treatment of hyperkalemia.
Receive News & Ratings for Relypsa Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Relypsa Inc. and related companies with MarketBeat.com's FREE daily email newsletter.